Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Humacyte, Inc. develops bioengineered human tissues and acellular vascular grafts for medical use. Its core products include the FDA-approved Symvess ATEV for vascular repair, reconstruction, and replacement, targeting trauma, dialysis access, PAD, and cardiac surgery markets. The company leverages scalable manufacturing and proprietary technology to produce off-the-shelf, universally implantable tissues with low infection and rejection rates, aiming to improve patient outcomes and transform regenerative medicine.
This description was generated via AI from an annual report. Updated about 1 year ago.